Dexilant Labeling Updated with Plavix Coadministration Information

Takeda announced that it has updated the product labeling for Dexilant (dexlansoprazole) to include information demonstrating that Dexilant had no clinically important effect on exposure to the active metabolite of clopidogrel (Plavix; Bristol-Myers Squibb and Sanofi) or clopidogrel-induced platelet inhibition.

Nexium IV Gains Indication for GERD in Pediatric Patients

AstraZeneca announced that the FDA has approved Nexium IV (esomeprazole sodium for injection) for use in children >1 month of age for the short-term treatment of gastroesophageal reflux disease (GERD) with erosive esophagitis when oral therapy is not possible or appropriate.